ABSTRACT
BACKGROUND: The role of bevacizumab in metastatic breast cancer is controversial. Identification of predictive biomarkers could help to select patients who really benefit from it. We evaluated the association of angiogenesis-related gene polymorphisms with the treatment outcome of bevacizumab in metastatic breast cancer patients. PATIENTS AND METHODS: eNOS-786T/C and -894G/T, IL-8-251T/A genomic polymorphisms were assessed in 31 metastatic breast cancer patients treated with bevacizumab plus chemotherapy in the first-line setting. Testing for association between each polymorphism and treatment outcome was performed. RESULTS: Patients with IL-8 251 AA genotype showed a significantly lower progression-free survival in each combination comparison: "TT" vs "AA" (13 vs 8 months; p = 0.008); TT vs TA vs AA (13 vs 11 vs 8 months; p = 0.02); TT vs TA +AA (13 vs 11 months; p = 0.01); TT + TA vs AA (12 vs 8 months; p = 0.01) and a lower overall survival when compared with TT +TA genotype (26 vs 51 months, p = 0.04). Patients carrying eNOS 894 TT genotype showed a statistically significant lower progression-free survival than patients with GG genotype (11.5 vs 26.5 months; p = 0.04) with no differences in the overall survival. No association with response rate was found with any of the polymorphisms analyzed. CONCLUSION: These findings suggest that IL-8 251T/A and eNOS-894 G/T polymorphisms might have a role in predicting treatment outcome of bevacizumab in metastatic breast cancer. Our results are hypothesis generating and need to be confirmed in larger clinical trials.
Subject(s)
Bevacizumab/therapeutic use , Breast Neoplasms/drug therapy , Interleukin-8/genetics , Nitric Oxide Synthase Type III/genetics , Polymorphism, Single Nucleotide , Adult , Aged , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Female , Genetic Association Studies , Humans , Middle Aged , Polymorphism, Restriction Fragment Length , Prognosis , Retrospective Studies , Treatment OutcomeABSTRACT
The authors describe a case of anisakiasis in Sicily. The diagnosis was based on the knowledge that a contaminated fish, Lepidopus caudatus, had probably been absorbed, as well as on clinical intestinal symptoms, intestinal lesions observed by endoscopy and O.G.D.S, duodenal infiltration by eosinophilic polymorphonuclear, positive ELISA anisakis serology and successful treatment by albendazole.
Subject(s)
Anisakiasis/diagnosis , Animals , Anisakiasis/pathology , Anisakiasis/transmission , Anisakis/immunology , Antibodies, Helminth/blood , Eosinophilia , Fishes/parasitology , Food Contamination , Humans , Intestinal Mucosa/pathology , Male , Middle AgedABSTRACT
Background. The role of bevacizumab in metastatic breast cancer is controversial. Identification of predictive biomarkers could help to select patients who really benefit from it. We evaluated the association of angiogenesis-related gene polymorphisms with the treatment outcome of bevacizumab in metastatic breast cancer patients. Patients and methods. eNOS-786T/C and -894G/T, IL-8-251T/A genomic polymorphisms were assessed in 31 metastatic breast cancer patients treated with bevacizumab plus chemotherapy in the first-line setting. Testing for association between each polymorphism and treatment outcome was performed. Results. Patients with IL-8 251 AA genotype showed a significantly lower progression-free survival in each combination comparison: "TT" vs "AA" (13 vs 8 months; p = 0.008); TT vs TA vs AA (13 vs 11 vs 8 months; p = 0.02); TT vs TA +AA (13 vs 11 months; p = 0.01); TT + TA vs AA (12 vs 8 months; p = 0.01) and a lower overall survival when compared with TT +TA genotype (26 vs 51 months, p = 0.04). Patients carrying eNOS 894 TT genotype showed a statistically significant lower progression-free survival than patients with GG genotype (11.5 vs 26.5 months; p = 0.04) with no differences in the overall survival. No association with response rate was found with any of the polymorphisms analyzed. Conclusion. These findings suggest that IL-8 251T/A and eNOS-894 G/T polymorphisms might have a role in predicting treatment outcome of bevacizumab in metastatic breast cancer. Our results are hypothesis generating and need to be confirmed in larger clinical trials (AU)
No disponible
Subject(s)
Humans , Male , Female , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Biomarkers/metabolism , Neovascularization, Physiologic/genetics , Amplified Fragment Length Polymorphism Analysis/methods , Pharmaceutical Preparations/administration & dosage , Therapeutics/methods , Survivorship/psychology , Clinical Trials as Topic/methods , Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy , Biomarkers/analysis , Neovascularization, Physiologic/physiology , Amplified Fragment Length Polymorphism Analysis/standards , Pharmaceutical Preparations/metabolism , Therapeutics/instrumentation , Survivorship/physiology , Clinical Trials as TopicABSTRACT
The AA. refer on the first Italian case of amoebae "Limax" primitive myelitis in a 25-year-old man. Microscopical observation showed amoebae free-living, but their cultivation and identification were not possible. The patient recovered because of the propriety of diagnosis and therapy with amphotericin B.